The Annals Evolution of Clinical Pharmacy | Now Available
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     

The Annals of Pharmacotherapy: Vol. 37, No. 2, pp. 274-278. DOI 10.1345/aph.1C314
© 2003 Harvey Whitney Books Company.
This Article
Right arrow Résumé Freely available
Right arrow Extracto Freely available
Right arrow Full Text
Right arrow PDF
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Backes, J. M
Right arrow Articles by Howard, P. A
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Backes, J. M
Right arrow Articles by Howard, P. A

Association of HMG-CoA Reductase Inhibitors with Neuropathy

James M Backes, PharmD

Clinical Assistant Professor, Department of Pharmacy Practice and Lipid, Atherosclerosis, Metabolic and LDL-Apheresis Clinic, University of Kansas Medical Center, Kansas City, KS

Patricia A Howard, PharmD FCCP BCPS (AQ Cardiology)

Professor and Vice Chair, Department of Pharmacy Practice, School of Pharmacy, University of Kansas, Kansas City

Reprints: James M Backes PharmD, Department of Pharmacy Practice, University of Kansas Medical Center, 3901 Rainbow Blvd., Kansas City, KS 66160-7231, FAX 913/588-2355, E-mail jbackes{at}kumc.edu

OBJECTIVE: To review the possible association between statins and peripheral neuropathy.

DATA SOURCES: Literature was obtained from MEDLINE (1984–September 2002) and International Pharmaceutical Abstracts (1970–June 2002). Key search terms included statin, neuropathy, and HMG-CoA reductase inhibitor.

DATA SYNTHESIS: Epidemiologic studies and case reports suggest an increased risk of peripheral neuropathy with statin drugs. Most patients were receiving long-term therapy, although the onset was highly variable. The majority of cases were at least partially reversible with drug cessation. Specific risk factors or mechanisms have not been identified.

CONCLUSIONS: Observational data suggest a link between chronic statin use and increased risk of peripheral neuropathy. However, the risk appears to be small relative to the significant cardioprotective benefits.

Key Words: HMG-CoA reductase inhibitors, neuropathy, statins

Published Online, January 3, 2003. www.theannals.com, DOI


This article has been cited by other articles:


Home page
 Arch Intern MedHome page
G. Tsivgoulis, K. Spengos, N. Karandreas, M. Panas, A. Kladi, and P. Manta
Presymptomatic neuromuscular disorders disclosed following statin treatment.
Arch Intern Med, July 24, 2006; 166(14): 1519 - 1524.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
T. B. Vaughan and D. S.H. Bell
Statin Neuropathy Masquerading as Diabetic Autoimmune Polyneuropathy
Diabetes Care, August 1, 2005; 28(8): 2082 - 2082.
[Full Text] [PDF]

Home page
 Diabetes CareHome page
A. J.M. Boulton, R. A. Malik, J. C. Arezzo, and J. M. Sosenko
Diabetic Somatic Neuropathies
Diabetes Care, June 1, 2004; 27(6): 1458 - 1486.
[Full Text] [PDF]

Home page
 Toxicol PatholHome page
J. S. MacDonald and M. M. Halleck
The Toxicology of HMG--CoA Reductase Inhibitors: Prediction of Human Risk
Toxicol Pathol, February 1, 2004; 32(2_suppl): 26 - 41.
[Abstract] [PDF]


homecopy help contact us subscription past issues search current issue
Copyright © 2003 by Harvey Whitney Books Company.